Product Overview

Glimith MF2 1000 SR is a combination antidiabetic formulation containing Glimepiride IP 2 mg and Metformin Hydrochloride IP 1000 mg (Sustained Release), developed for the effective management of Type 2 Diabetes Mellitus. This dual-action therapy combines the insulin-secreting action of Glimepiride with the insulin-sensitizing effects of sustained-release Metformin to provide comprehensive blood glucose control.

Glimepiride stimulates the pancreatic beta cells to release insulin, helping reduce blood glucose levels, while Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity. The sustained-release formulation of Metformin ensures prolonged therapeutic action, improved gastrointestinal tolerability, and convenient once-daily dosing, supporting better treatment adherence.

Glimith MF2 1000 SR is commonly prescribed when lifestyle modifications or monotherapy are insufficient to achieve adequate glycemic control. It may be used as part of a comprehensive diabetes management plan that includes a balanced diet, regular physical activity, and routine blood glucose monitoring. By effectively controlling fasting and postprandial blood glucose levels, the formulation helps reduce the risk of long-term diabetes-related complications.

Manufactured under stringent pharmaceutical quality standards, Glimith MF2 1000 SR provides consistent efficacy, safety, and reliability, making it a trusted therapeutic option for healthcare professionals managing Type 2 Diabetes Mellitus.

How It Works

Glimepiride stimulates insulin secretion from the pancreatic beta cells, helping lower blood glucose levels. Metformin Hydrochloride reduces glucose production in the liver, decreases intestinal glucose absorption, and improves the body’s sensitivity to insulin. Together, these complementary mechanisms provide effective and sustained glycemic control while supporting overall metabolic health.

Therapeutic Applications

Glimith MF2 1000 SR may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Inadequately Controlled Blood Glucose Levels
• Long-Term Glycemic Management
• Combination Antidiabetic Therapy
• Patients requiring dual-mechanism glucose control

Key Benefits

• Dual-action therapy for comprehensive blood glucose management.
• Combines Glimepiride with Sustained-Release Metformin.
• Helps maintain stable fasting and postprandial blood glucose levels.
• Improves insulin secretion and insulin sensitivity.
• Convenient sustained-release formulation for improved patient compliance.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Glimith MF2 1000 SR undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Glimith MF2 1000 SR should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.